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 53 
Abstract  54 
We report SARS-CoV-2 spike H69/V70 in multiple independent lineages, often occurring 55 
after acquisition of the receptor binding motif replacements such as N439K and Y453F 56 
known to increase binding affinity to the ACE2 receptor and confer antibody escape. In vitro, 57 
we show that whilst H69/V70 itself is not an antibody evasion mechanism, it increases 58 
infectivity associated with enhanced incorporation of cleaved spike into virions. H69/V70 is 59 
able to partially rescue infectivity of S proteins that have acquired N439K and Y453F escape 60 
mutations by increased spike incorporation. In addition, replacement of H69 and V70 61 
residues in B.1.1.7 spike (where H69/V70 naturally occurs) impairs spike incorporation and 62 
entry efficiency of B.1.1.7 spike pseudotyped virus. B.1.1.7 spike mediates faster kinetics of 63 
cell-cell fusion than wild type Wuhan-1 D614G, depend nt on H69/V70. Therefore, as 64 
H69/V70 compensates for immune escape mutations that impair infectivity, continued 65 














SARS-CoV-2’s spike surface glycoprotein engagement of human angiotensin-converting 73 
enzyme (hACE2) is essential for virus entry and infection(Zhou et al., 2020), and the receptor 74 
is found in respiratory and gastrointestinal tracts(Sungnak et al., 2020). Despite this critical 75 
interaction and the imposed constraints, it appears the receptor binding  domain (RBD) is 76 
relatively tolerant to mutations(Starr et al., 2020b; Thomson et al., 2020), raising the real 77 
possibility of virus escape from past infection or vaccine-induced immunity(Cele et al., 2021; 78 
Collier et al., 2021; Gupta, 2021; Madhi et al., 2021) and monoclonal antibody 79 
treatments(Starr et al., 2021). Spike mutants exhibiting reduced susceptibility to neutralising 80 
antibodies have been identified in in vitro screens(Greaney et al., 2021; Greaney et al., 2020; 81 
Starr et al., 2020a), and some of these mutations have been found in clinical isolates(Choi et 82 
al., 2020).  83 
 84 
Studying SARS-CoV-2 chronic infections can give insight into virus evolution that would 85 
require many chains of acute transmission to generate. This is because the majority of 86 
infections arise as a result of early transmission during pre or asymptomatic phases prior to 87 
peak adaptive responses, and virus adaptation not observed as the virus is usually cleared by 88 
the immune response(He et al., 2020; Mlcochova et al., 2020b). We recently documented de89 
novo emergence of antibody evasion mutations mediated by S gene mutations in an 90 
individual treated with convalescent plasma (CP)(Kemp et al., 2021). In addition, a 91 
chronically infected immune suppressed individual was recently reported in Russia with 92 
emergence of Y453F, along with H69/V70(Bazykin et al., 2021). Deletions in other pa ts of 93 
the N-Terminal Domain (NTD) have been reported to arise in chronic infections(Choi et al., 94 
2020) and to reduce sensitivity to NTD-specific neutralising antibodies(McCallum et al., 95 
2021; McCarthy et al., 2021).  96 
 97 
Here we analyse global SARS-CoV-2 data and find H69/V70 occurs independently often 98 
emerging after a significant RBD amino acid replacement such as Y453F and N439K, that 99 
are known to facilitate neutralising antibody escape or to alter ACE2 binding whilst incurring 100 








Although structural modelling indicates the H69/V70 is in an exposed loop that contracts post 102 
deletion, potentially altering an antigenic site, we report that the H69/V70 does not confer 103 
significantly reduced susceptibility to convalescent sera or mAb.  Functionally, we find that 104 
H69/V70 does increase spike infectivity and compensates for an infectivity defect resulting 105 
from RBD replacements N439K and Y453F. The infectivity increase is driven by higher 106 
levels of spike incorporation into virions. We demonstrate that the deletion is required for 107 
optimal infectivity of the 501Y.V1 (B.1.1.7) spike protein. We show that although B.1.1.7 108 
and wild type (WT) spike pseudotyped virus (PV)  have similar infectivity on a range of 109 
target cell types, the B.1.1.7 spike protein alone induces more rapid cell-cell fusion and 110 
formation of multinucleated cells. Repair of the two amino acids leads to not only reduced 111 
B.1.1.7 S incorporation into virions and impaired infectivity, but also reduces cell-cell fusion 112 
kinetics back to WT levels.  113 
 114 
Results 115 
Multiple occurrences and transmission of spike H69/V70 with and without S 116 
mutations 117 
The deletion H69/V70 is present in over 600,000 SAR-CoV-2 genome sequences 118 
worldwide, and has seen global expansion, particularly across much of Europe, Africa and 119 
Asia (Figure 1). H69/V70 is observed in multiple global lineages (Figure 1A). While 120 
variants with deletions in this region of spike are observed in GISAID13, the earliest 121 
unambiguous sequences that include the H69/V70 were detected on a D614 background in 122 
January 2020 (USA and Thailand). The earliest H69/V70 detected on a D614G background 123 
was in Sweden in April 2020. Prevalence of H69/V70 has increased since August 2020 124 
(Figure 1B). Further analysis of sequences revealed, firstly, that single deletions of either 125 
H69 or V70 were uncommon and, secondly, some lineages of H69/V70 alone were present, 126 
as well as H69/V70 in the context of other mutations in spike, specifically those in the 127 
RBM (Figure 1).  128 
 129 
H69/V70 is not a neutralising antibody escape mechanism   130 
We hypothesised that H69/V70 might confer reduced susceptibility to neutralising 131 
antibodies. We first examined the protein structural context of H69/V70 for clues regarding 132 
alterations in epitopes (Figure 2A, B).  In the absence of experimentally derived structural 133 








modelled in silico. The H69/V70 deletion was predicted to alter the conformation of a 135 
protruding loop comprising residues 69 to 76, pulling t in towards the NTD (Figure 2B). In 136 
the post-deletion structural model, the positions of the alpha carbons of residues either side of 137 
the deleted residues, Ile68 and Ser71, were each predicted to occupy positions 2.9Å from the 138 
positions of His69 and Val70 in the pre-deletion structure. Concurrently, the positions of 139 
Ser71, Gly72, Thr73, Asn74 and Gly75 are predicted to have changed by 6.5Å, 6.7Å, 6.0Å, 140 
6.2Å and 8Å, respectively, with the overall effect of these residues moving inwards, resulting 141 
in a less dramatically protruding loop.  142 
 143 
This predicted change in the surface of spike could be consistent with antibody evasion. To 144 
test this we explored whether H69/V70 conferred reduced susceptibility to neutralising 145 
antibodies in sera from fifteen recovered individuals (Figure 2C, D). We performed serial 146 
dilutions of sera before mixing with lentiviral particles pseudotyped with Spike proteins with 147 
and without H69/V70 (with virus input normalised for infectivity). We plotted infection of 148 
target cells as a function of serum dilution (Figure 2D). All but two sera demonstrated clear 149 
titratable neutralisation of both wild type and H69/V70 virus. There was no overall change 150 
in susceptibility to serum neutralisation for H69/V70 relative to wild type (Figure 2C), but 151 
there was a proportion of individuals with slightly increased neutralisation sensitivity of 152 
H69/V70 (Figure 2C, D). To further explore the role for H69/V70 in inducing immune 153 
escape, we tested the binding of 12 NTD-mAbs to wildtype and H69/V70 NTD by biolayer 154 
interferometry (Figure 2E-G). All the NTD-mAbs showed less than 2-fold decrease in 155 
binding to H69/V70 compared to WT. These data suggest that H69/V70 does not 156 
represent an important antibody escape mechanism.  157 
 158 
H69/V70 spike enhances infectivity associated with increased cleaved S incorporation 159 
We hypothesised that the deletion might alternatively enhance virus infectivity. In the 160 
absence of virus isolates we used a lentiviral PV approach to test the impact of H69/V70 on 161 
virus spike protein mediated entry. A D614G bearing Wuhan-1 spike expressing DNA 162 
plasmid (WT) was co-transfected in HEK 293T producer cells along with plasmids encoding 163 
lentiviral capsid and genome for luciferase. Infectivity was adjusted for input reverse 164 
transcriptase activity; we observed a two-fold increase in PV infectivity of H69/V70 as 165 
compared to WT in HeLa cervical epithelial cells stably expressing human ACE2 (Figure 3A, 166 








in context of over-expression of ACE2/TMPRSS2 (HEK 293T cells transiently transfected 168 
with ACE2, or ACE2 and TMPRSS2 and A549 lung cells stably expressing ACE2 and 169 
TMPRSS2(Rihn et al., 2021)) or endogenous levels of receptors in Calu-3 lung 170 
adenocarcinoma cells (Figure 3A).    171 
 172 
Western blotting for S2 spike indicated that a higher amount of cleaved spike in H69/V70 173 
bearing virions and in the 293T producer cell lysate . We also noted a corresponding 174 
reduction in uncleaved full length (FL) spike (Figure 3C). Densitometric analysis of spike 175 
and p24 from western blots in multiple experiments showed almost a two-fold increase in 176 
spike:p24 ratio as well as an increased ratio in S2:FL cleavage for the H69/V70, indicating 177 
increased spike incorporation into virions might explain the increase in infectivity (Figure 178 
3D, E). To verify that this increased in S from producer cells was not specific to HEK 293T 179 
cells we also transfected the human lung epithelial cell line H1299(Zhang et al., 2020) with 180 
spike and lentiviral packaging plasmids. We again observed that viruses from these cells had 181 
a two fold increased infectivity in target cells (Figure 3F). In addition the increased total and 182 
cleaved S levels were recapitulated both in the cell lysates and purified virions from these 183 
lung cells (Figure 3G, H). Therefore we conclude that the increased S cleavage and its 184 
incorporation observed in producer cells and pseudotyped virions is a generalised 185 
phenomenon for H69/V70 S. In order to explore whether D614G was required for this 186 
enhanced spike cleavage and infectivity, we generated PV bearing D614 spike with and 187 
without the H69/V70 followed by infection in HEK293T cells. We observed a similar two 188 
fold enhancement of infection and a proportional increase in spike incorporation as we did 189 
for D614G spike pseudotyped viruses (Supplementary Figure 1A, B). Finally, to exclude the 190 
possibility that increased incorporation of S was specific for pseudotyped lentiviral particles, 191 
we generated coronavirus-like particles by co-transfection of WT or H69/V70 S with 192 
SARS-CoV-2 (M)embrane, (E)nvelope and (N)ucleocapsid roteins as previously described 193 
(Swann et al., 2020; Yurkovetskiy et al., 2020). Compared with levels of N, levels of cleaved 194 
S in coronavirus-like particles were again enhanced in the presence of the H69/V70 deletion 195 
(Supplementary Figure 1 C,D). 196 
 197 
Enhanced infectivity of H69/V70 spike is not correlated with cleavage or entry route 198 
SARS-CoV-2 entry into target cells is thought to take place by two distinct routes following 199 








spike with pH dependent fusion in the endosome. The second route involves fusion at the 201 
plasma membrane with cleavage via the plasma membrane associated protease TMPRSS2.  202 
In order to determine the mechanism by which increased spike cleavage in the context of 203 
H69/V70 might impact entry, we used inhibitors of furin cleavage (CMK) and protease 204 
inhibitors specific to endosomal (ED64D) and plasma embrane fusion (camostat) entry 205 
routes (Figure 4A). We firstly treated producer cells with CMK and found that indeed CMK 206 
inhibits spike S1/S2 cleavage in the producer cells transfected with S ∆H69/V70 plasmid, and 207 
that the spikes with altered S1/S2 cleavage are incorporated onto the virions (Figure 4B). We 208 
found that CMK treatment, whilst reducing S1/S2 cleavage, did not decrease the PV infection 209 
in a variety of target cells (Figure 4C) suggesting he increased infectivity in H69/V70 is not 210 
due to more efficient cleavage of spike. To confirm our findings, we generated a spike 211 
lacking the polybasic cleavage site with or without ∆H69/V70 and tested PV infectivity on 212 
293T cells overexpressing ACE2 and TMPRSS2. We found that deletion of the PBCS led to 213 
increased infectivity of the PV, as observed previously for mutated PBCS20. As expected, 214 
deletion of the PBCS did not alter the enhancing effect of ∆H69/V70 on PV infectivity 215 
(Figure 4D).  216 
 217 
The altered level of S1/S2 cleavage in SARS-CoV-2 has been linked to its dependence on 218 
viral entry through either membrane fusion or endocyt sis in 293T and A549 cells(Peacock et 219 
al., 2020; Winstone et al., 2021). We therefore hypothesised that the increased spike cleavage 220 
of H69/V70 S could influence the route of entry. To probe this, spike pseudotyped 221 
lentiviruses bearing either WT spike, ∆H69/V70 spike or VSV-G were next used to transduce 222 
293T-ACE2 or 293T-ACE2/TMPRSS2 cells in the presence of either E64D or camostat at 223 
different drug concentrations (Figure 4E). As expected, the VSV-G pseudotyped particles 224 
were not affected by addition of either E64D or camostat. Consistent with previous 225 
observations, WT PV utilised endocytosis in the absence of TMPRSS2(Peacock et al., 2020) 226 
but where TMPRSS2 was expressed, plasma membrane fusion became the dominant 227 
route(Papa et al., 2021; Winstone et al., 2021). However, there were no differences between 228 
WT and ∆H69/V70 in relative utilisation of the endosomal versus plasma membrane entry 229 
routes. We conclude that the enhanced spike cleavag, whilst notable in ∆H69/V70, does not 230 
appear responsible for the increased infectivity of ∆H69/V70 spike observed in these cell line 231 









H69/V70 spike compensates for reduced infectivity of RBD escape mutants  234 
We next examined in greater detail the SARS-CoV-2 lineages where S mutations in the RBD 235 
were identified at high frequency and where H69/V70 co-occurs. For example, N439K, an 236 
amino acid replacement reported to be defining variants increasing in numbers in Europe and 237 
other regions(Thomson et al., 2020) (Figure 1 and 5A) now mostly co-occurs with 238 
H69/V70. N439K appears to have reduced susceptibility to some convalescent sera as well 239 
as monoclonal antibodies targeting the RBD, whilst ncreasing affinity for ACE2 in 240 
vitro(Thomson et al., 2021). The first lineage possessing N439K (and not H69/V70), 241 
B.1.141 is now extinct(Thomson et al., 2020). A second lineage with N439K, B.1.258, later 242 
emerged and subsequently acquired H69/V70 leading to the initial rapid increase in the 243 
frequency of viruses possessing this deletion, spreading into Europe (Figure 1A) (Brejová et 244 
al., 2021).  245 
 246 
The second significant cluster with H69/V70 and RBD mutants involves Y453F, another 247 
spike RBD mutation that increases binding affinity to ACE2(Starr et al., 2020b) and has been 248 
found to be associated with mink-human infections(Munnink et al., 2020). Y453F has also 249 
been described as an escape mutation for mAb REGN10933 and shows reduced susceptibility 250 
to convalescent sera (Baum et al., 2020; Hoffmann et al., 2021), and is possibly a T cell 251 
escape mutation(Motozono et al., 2021). The H69/V70 was first detected in the Y453F 252 
background on August 24th 2020 and thus far appears limited to Danish sequences (Figure 1, 253 
Figure 5B), although an independent acquisition wasrecently reported along with H69/V70 254 
in an immune compromised Russian individual with chronic infection(Bazykin et al., 2021).  255 
 256 
We hypothesised that H69/V70 might have arisen after Y453F and N439K in order to 257 
compensate for potential loss of infectivity that hs been reported for these RBD mutants 258 
previously(Motozono et al., 2021; Sungnak et al., 2020). We therefore generated mutant 259 
spike plasmids bearing RBD mutations Y453F and N439K (Figure 5C) both with and without 260 
H69/V70 and performed infectivity assays in the lentiviral pseudotyping system. RBD 261 
mutations reduced infectivity of Spike relative to WT by around 2 fold (Figure 5D) and was 262 
partially rescued by H69/V70. Based on observations of the impact of H69/V70 on spike 263 
incorporation in WT (Figure 3D), we predicted that the mechanism of increased infectivity 264 
for H69/V70 in context of RBD mutations might be similar. The analysis of virions from 265 








As observed for WT, we also observed increased cleaved S2:FL when H69/V70 was 267 
present along with the RBD mutants in PV (Figure 5E, G). 268 
 269 
H69/V70 is required for optimal B.1.1.7 spike S2 incorporation and infectivity  270 
A lineage containing the H69/V70 deletion was first detected in the UK with the RBD 271 
mutation N501Y along with multiple other spike and other mutations (Figure 1, 272 
Supplementary Figure 2). These UK sequences were subseq ently named as B.1.1.7, termed 273 
a variant of concern (VOC), as they are associated with higher transmission rate(Volz et al., 274 
2021b). Subsequently B.1.1.7 has spread rapidly to over 100 countries exemplifying a new 275 
chapter in the pandemic, with additional VOCs detect d in other geographical locations. In 276 
addition to RBD N501Y + NTD H69/V70, B.1.1.7 is defined by further S mutations across 277 
S2 (T716I, S982A and D1118H), and S1 (Y144, A570D, P681H), see figure 6A (Rambaut 278 
A., 2020). The available sequence data did not enabl  determination of whether the B.1.1.7 279 
mutations N501Y + H69/V70 arose as a result of a N501Y virus acquiring H69/V70, or 280 
vice versa, though a UK B.1.1.7 sequence was identifi d with N501Y, A570D, H69/V70 281 
and D1118H (Supplementary Figure 2).  282 
 283 
In order to ascertain whether H69V70 represented a target for neutralising antibodies in the 284 
context of B.1.1.7, we first tested 12 NTD-specific mAbs isolated from 4 individuals that 285 
recovered from WT SARS-CoV-2 infection with an in-vitro PV neutralisation assay using 286 
WT SARS-CoV-2 S, the B.1.1.7 S or the B.1.1.7 S with reversion of H69/V70 deletions 287 
(B.1.1.7 H69/V70) pseudotyped viruses in VeroE6 target cells expressing TMPRSS2. 288 
(Supplementary Table 2). We found that 7 out of 12 NTD-specific mAbs (58%) showed a 289 
marked decrease or complete loss of neutralising activity to both B.1.1.7 and B.1.1.7 290 
H69/V70 (>30 fold-change reduction), suggesting that in a sizeable fraction of NTD 291 
antibodies the H69/V70 deletion is not responsible for their loss of neutralising activity 292 
(Supplementary Figure 3). The remaining 5 mAbs showed a partial reduction (2-to-10 fold) 293 
in B.1.1.7 neutralisation that was not rescued by reve sion of H69/V70 deletions.  294 
 295 
Given our data on introduction of H69/V70 into WT (Figure 3), we hypothesised that 296 
H69/V70 was selected in the evolution of B.1.1.7 in order to increase viral entry. We 297 
predicted that the replacement of H69 and V70 would impair the infectivity of B.1.1.7 PV 298 








PV versus B.1.1.7 PV with H69 and V70 restored to B.1.1.7 spike. We observed that 300 
infectivity of B.1.1.7 infectivity was slightly lower than WT (Figure 6B). As expected, we 301 
observed a significant reduction in infectivity for vi uses where the H69 and V70 had been 302 
re-inserted across a number of cell types, including H1299 expressing endogenous levels of 303 
ACE2 and TMPRSS2 receptors (Figure 6B, C).  When we measured spike incorporation into 304 
virions we found that the reduced infectivity of the B.1.1.7 with replaced H69 V70 was 305 
associated with reduced spike:p24 and S2:FL ratio as expected (Figure 6D-G).  306 
 307 
B.1.1.7 spike mediates faster syncytium formation and is H69/V70 dependent 308 
Previous reports have shown that SARS-CoV-2 spike protein localises to the cell host plasma 309 
membrane and possesses high fusogenic activity, triggering the formation of large multi-310 
nucleated cells (named syncytia) n vitro and in vivo potentially providing an additional and a 311 
more rapid route for virus disseminating among neighbour cells(Bussani et al., 2020; Cattin-312 
Ortolá et al., 2020; Papa et al., 2021). The role of syncytium formation in viral replication 313 
and pathogenesis of severe COVID-19 has been reported and may be druggable process to 314 
treat COVID-19 pathology(Braga et al., 2021). We expr ssed B.1.1.7 spike and a B.1.1.7 315 
with restored H69 and V70 together with the mCherry fluorescent protein in 293T cells and 316 
labelled Vero cells with a green fluorescent dye (Figure 7A). All spike constructs showed 317 
similar protein expression and achieved similar cell- ll fusion by 16 hours. B.1.1.7 appeared 318 
to mediate more cell-cell fusion events over earlier time points with the colour overlap area 319 
being 2-3 times greater for B.1.1.7 as compared to wild type at 6 hours post mixing. 320 
Interestingly, this enhancement was abrogated by re-insertion of H69 and V70 residues 321 
(Figure 7B-D). We conclude that B.1.1.7 spike mediates faster fusion kinetics than wild type 322 
bearing D614G Wuhan-1 spike, and that this is dependent on H69/V70. 323 
 324 
H69/V70 does not enhance infectivity of bat coronavirus RaTG13 spike  325 
Finally, to investigate the importance of this part of spike beyond SARS-CoV-2 to other 326 
coronaviruses with zoonotic potential, we examined the 69/70 region of spike in a set of other 327 
known sarbecoviruses (Supplementary Figure 4A-C). We observed substantial variability in 328 
the region, resulting in frequent indels, with some viruses including SARS-CoV having 6-7 329 
amino acid deletions (Supplementary Figure 4B). This is indicative of high structural 330 
plasticity in this protein region that could allow the sarbecoviruses to alter their Spike 331 








and after RaTG13 is the cluster of 5 CoVs sampled in trafficked pangolins in the Guangxi 333 
province(Lam et al., 2020). Inspection of the 69/70 region in these virus sequences raises the 334 
interesting observation that one of the five viruses in the cluster, P2V, has amino acids 69H 335 
and 70L present, while the other four have a double amino acid deletion (Supplementary 336 
Figure 4A-C). Given that SARS-CoV-2 and RaTG13 have the homologous HV insertion at 337 
these positions, one explanation is that the proximal common ancestor between SARS-CoV-2 338 
and the Guangxi pangolin cluster had the insertion, which was then lost while circulating in 339 
the pangolin population, similar to observations with SARS-CoV-2 in humans. Yet, the fact 340 
that P2V was cultured in Vero E6 cells prior to sequ ncing (contrary to the other 4, 341 
sequenced directly from the pangolin sample) raises the possibility of this being an 342 
independent insertion, favoured as a monkey cell line specific adaptation. Interestingly, the 343 
double amino acid indel in the pangolin viruses is in-frame in contrast to SARS-CoV-2.  344 
 345 
Furthermore, the two almost identical bat viruses recently sequenced from Cambodia samples 346 
– RShSTT182 and 200(Hul et al., 2021) possess an H69V70 insertion despite being more 347 
distantly related to SARS-CoV-2 for this region of Spike (Supplementary Figure 4A-C). This 348 
independent occurrence of the insertion is suggestive of context dependent selective pressures 349 
playing a role in recurring gain and loss of these two residues in the Sarbecoviruses. To test 350 
whether the fitness effect associated with acquisition of H69/V70 is specific to SARS-CoV-351 
2 and not other Sarbecovirus spike backgrounds, we cloned full length S from RaTG13 and 352 
generated pseudotyped lentiviruses expressing RaTG13 Spike protein as well as a RaTG13 S 353 
H69/V70 counterpart. We observed that cleaved and uncleaved S expression levels in PV 354 
did not differ between WT and the H69/V70 RaTG13 spike, and that there was no 355 
difference in infectivity on target cells expressing ACE2 or both ACE2 and TMPRSS2 356 
(Supplementary Figure 4D-E).  This result suggests that as one would expect, the enhancing 357 
effect of H69/V70 on spike levels and infectivity is specific to spike-background. 358 
 359 
Discussion 360 
We have presented data demonstrating multiple, independent, and circulating lineages of 361 
SARS-CoV-2 variants bearing spike H69/V70. This recurring deletion spanning six 362 
nucleotides is due to an out of frame deletion of six nucleotides, and occurs in the terminal 363 
loop of a helix loop motif within the predicted RNA structure, as do other NTD deletions 364 








P.1(Supplementary Figure 5). Stable helix loop motifs are associated with 366 
pausing/dissociation events in reverse transcriptase(Harrison et al., 1998) . Since all nucleic 367 
acid polymerases have a common ancestor with homologous dNTP binding motifs and 368 
similar global structures(Delarue et al., 1990; Ollis et al., 1985; Sousa et al., 1993)  it is 369 
probable that all RNA polymerases use similar mechanisms for transcript termination(Reeder 370 
and Lang, 1994).  A recent in-cell biochemical analysis of SARS-CoV2 RNA structure 371 
showed nucleotide reactivity consistent with this model within these stem-loops(Huston et 372 
al., 2021). These analyses provide a rationale for preferential emergence of H69/V70 and 373 
other deletions such as the well described NTD-antibody escape deletion Y144(Chi et al., 374 
2020; McCarthy et al., 2020, 2021) (in B.1.1.7 and the recently reported B.1.525) at the 375 
terminal loops of helical loop motifs. H69/V70 itself has frequently followed immune 376 
escape associated amino acid replacements in the RBD (eg N439K and Y453F), and is 377 
specifically found in the B.1.1.7 variant known to have higher transmissibility(Volz et al., 378 
2021a) and possibly pathogenicity(Davies et al., 2021).  379 
 380 
We find that H69/V70 does not significantly reduce sensitivity of spike to neutralising 381 
antibodies in serum from a group of recovered individuals or binding of multiple mAb 382 
directed against the NTD. In addition we have shown that repair of H69/V70 does not 383 
appreciably alter the potency of NTD antibodies against the B.1.1.7 spike. Thus the deletion 384 
is unlikely to represent an immune escape mechanism. Instead, our experimental results 385 
demonstrate that the H69/V70 deletion is able increase infectivity of Wuhan-1 D614G spike 386 
pseudotyped virus, as well as pseudotyped virus bearing the additional RBD mutations 387 
N439K or Y453F,  explaining why the deletion is often observed after these immune escape 388 
mutations that carry infectivity cost(Motozono et al., 2021; Sungnak et al., 2020). We show 389 
that the mechanism of enhanced infectivity across the RBD mutations tested is associated 390 
with greater spike incorporation into virions where th  H69/V70 deletion is present. The 391 
phenotype is also independent of producer cell used. Importantly, we were able to 392 
recapitulate the H69/V70 phenotype in a spike protein that did not have the D614G 393 
mutation, indicating that D614G is not involved in the mechanism. These observations are 394 
supported by H69/V70 being observed in D614 viruses in Jan 2020 both in the US and 395 
Thailand. Although we did not use a replication competent system, a recent pre-print reports 396 
H69/V70 mutated Washington strain virus isolate as conferring increased replication in cell 397 








cell culture during remdesivir selection experiments with replication competent virus, 399 
consistent with a replication advantage (Szemiel et a ., 2021).   400 
 401 
We have found consistent differences in S, as well as cleaved S, in the producer cell and its 402 
incorporation into PV particles when comparing H69/V70 to a Wuhan-1 spike (both with 403 
D614G). This could be explained by stability during i tracellular trafficking or the route 404 
taken to the surface, differences in post-translation l modification of the S-protein, or 405 
membrane characteristics at the site of virus budding or virus like particles. As the amount of 406 
S incorporation into virions reflects the S in the cells, virion formation is likely unaffected by 407 
H69/V70. Interestingly, although pharmacological inhibition of furin by CMK in producer 408 
cells did prevent S1/S2 cleavage, and altered the balance of S2:FL spike in cells and virions, 409 
PV infectivity was not reduced by drug treatment. These data suggested that the increase in 410 
entry efficiency conferred by S H69/V70 is independent of spike S1/S2 cleavage. Similar 411 
findings on lack of relationship between balance of S2:FL and infectivity were reported in the 412 
context of furin knockout cells rather than furin inh bition with CMK(Papa et al., 2021). In 413 
addition, a recent report on the S1/S2 cleavage site mutation P681H demonstrated enhanced 414 
cleavage of Spike P681H was not associated with increased PV infectivity or cell fusion 415 
relative to WT (Lubinski et al., 2021). There may however be differences in vivo. 416 
 417 
We explored entry route of H69/V70 spike using cathepsin inhibition to block endosomal 418 
entry and camostat to block entry via plasma membrane fusion. H69/V70 spike was equally 419 
sensitive to camostat and the cathepsin inhibitor ED64 as WT, arguing that the efficiency of 420 
entry route usage is similar despite differences in cleaved spike. Although S1/S2 cleavage 421 
allows avoidance of endosome-associated IFITM restriction and appears critical for 422 
transmission in animal models(Peacock et al., 2020), cleaved spike may be less infectious if 423 
S1 is shed prematurely, therefore possibly conferring a disadvantage under some 424 
circumstances. In addition, Peacock et al showed that S1/S2 cleavage in the producer cell, 425 
conferred by a polybasic stretch at the cleavage site, is advantageous in cells expressing 426 
abundant TMPRSS2 but deleterious in cells lacking TMPRSS2(Peacock et al., 2020).  427 
 428 
The recently emergent lineage (B.1.1.7), bearing seven S mutations is now responsible for a 429 
new pandemic phase with a demonstrably more pathogenic(Davies et al., 2021) and 430 








suggests this lineage has either been introduced from a geographic region with very poor 432 
sampling or viral evolution may have occurred in a single individual in the context of a 433 
chronic infection(Kemp et al., 2020).  434 
 435 
We show that whilst B.1.1.7 spike has similar infectivity as wild type D614G spike, 436 
consistent with data on live B.1.1.7 virus in human airway epithelial cells(Brown et al., 437 
2021), but in contrast to another study that showed a difference in live virus with the 8 spike 438 
mutations(Liu et al., 2021). Importantly, however, we demonstrate loss of infectivity when 439 
the H69/V70 amino acids are replaced in B.1.1.7 S, accompanied as expected by reduced 440 
S1/S2 cleavage and reduced S incorporation into viri ns. These data point to epistatic 441 
interactions between observed mutations in spike of B.1.1.7, with a trade-off between 442 
mutations that incur virus entry cost with those that contribute to other activities such as 443 
immune evasion. 444 
 445 
Of greatest potential importance is our observation that B1.1.7 spike mediates faster 446 
syncytium formation and that this enhanced cell-cell fusion activity is dependent on 447 
H69/V70. Syncytium formation is a key feature of sever  and fatal COVID-19(Bussani et 448 
al., 2020), and implicated in elevated viral replicat on(Braga et al., 2021). We speculate that 449 
the increased fusogenicity of B.1.1.7 spike may contribute to higher mortality(Davies et al., 450 
2021) and transmissibility of B.1.1.7(Volz et al., 2021a).  451 
  452 
Limitations 453 
While we have combined epidemiological, evolutionary, protein and RNA structure and 454 
experimental data in our study, a limitation is the experiments were conducted with 455 
pseudotyped viruses (PV) and coronavirus like particles, rather than replication competent 456 
viruses. We also carried out experiments in cells overexpressing receptors, although results 457 
were recapitulated in lung cell lines expressing endogenous levels of ACE2 and TMPRSS2. 458 
 459 
The detection and surveillance of B.1.1.7 has been facilitated in the UK by the phenomenon 460 
of SGTF (S gene target failure) due to primers in the Thermofisher SARS-CoV-2 diagnostic 461 
qPCR assay used by a significant number of testing facilities. The S gene target (binding in 462 
the region of H69/V70) is one of three and therefor a marker for the spread of B.1.1.7 has 463 
been tracked by the loss of signal in the S gene target(Volz et al., 2021b). However recent 464 








B.1.1.7 detection as a significant H69/V70 lineage without other mutations in spike is 466 
circulating in the US, and a B.1.258 lineage with N439K with H69/V70, circulating in 467 
Slovakia/Czech republic(Brejová et al., 2021; Larsen and Worobey, 2020). Such examples 468 
highlight the need for genome sequencing to accompany novel approaches to diagnostics for 469 
variants. 470 
 471 
Given the emergence of multiple clusters of variants carrying RBD mutations and the 472 
H69/V70 deletion, limitation of transmission takes on a renewed urgency. As a further 473 
example, a new variant of concern bearing H69/V70 with E484K was recently identified 474 
(B.1.525).  Comprehensive vaccination efforts should be accelerated in order to limit 475 
transmission and acquisition of further mutations, and future vaccines could include 476 
H69/V70 in order to close this route for virus evolution, assuming that effective neutralising 477 
antibodies to this region are generated. Fortunately, our experiments with RaTG13 478 
demonstrate that the H69/V70 may not enhance infectivity of other bat S rbecoviruses with 479 
zoonotic potential.  480 
 481 
In summary we have found that a two amino acid deletion, H69/V70 promotes SARS-CoV-482 
2 spike incorporation into viral particles and increases infectivity by a mechanism that 483 
remains to be fully explained. This deletion has ari en multiple times and often after spike 484 
antibody escape mutations that reduce spike mediated entry efficiency. Critically, B1.1.7 485 
spike mediates faster syncitium formation and this enhanced cell-cell fusion activity is 486 
dependent on H69/V70. In addition, B.1.1.7 spike requires H69/V70 for optimal 487 
infectivity and we conclude therefore that H69/V70 enables SARS-CoV-2 to tolerate 488 
multiple immune escape mutations whilst maintaining infectivity and fusogenicity.  489 
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Figure titles and legends 521 
Figure 1. A. Global phylogeny of SARS-CoV-2 whole genome sequences highlighting 522 
those with specific mutations in spike: H69/V70, N439K, Y453F and N501Y. The tree is 523 
subsampled and tips are coloured by geographic region (see key). Grey bars on the right 524 
show the presence or absence of the deletion H69/V70 (del) and amino acid variants 525 
N439K, Y453F, and N501Y. PANGO Lineages are shown. Cumulative occurrences of 526 
SARS-CoV-2 sequences with the H69/V70 deletion by month for B. H69/V70 with or 527 
without N439K/ Y453F and C. H69/V70 with N501Y.  Indicated frequencies by month of 528 
the H69/V70 deletion are from the GISAID database (accessed 21st May 2021) by reporting 529 









Figure 2. Spike ∆H69/V70 does not reduce sensitivity to neutralising antibodies. Surface 532 
representation of spike homotrimer in open conformation (PDB: 7C2L) with each monomer 533 
shown in different shades of grey. On the monomer shown positioned to the right, the 534 
exposed loop consisting of residues 69-77 is shown in cyan and the neutralising antibody 535 
(4A8) binding NTD epitope in magenta. B Prediction of conformational change in the spike 536 
N-terminal domain due to deletion of residues His69 and Val70. The pre-deletion structure is 537 
shown in cyan, except for residues 69 and 70, which are shown in red. The predicted post-538 
deletion structure is shown in green. Residues 66-77 of the pre-deletion structure are shown 539 
in stick representation and coloured by atom (nitrogen in blue, oxygen in coral). Yellow lines 540 
connect aligned residues 66-77 of the pre- and post-dele ion structures and the distance of 6 541 
Å between aligned alpha carbons of Thr73 in the pre- and post-deletion conformation is 542 
labelled. C. Neutralisation of spike ∆H69/V70 pseudotyped virus and wild type (D614G 543 
background) by convalescent sera from 15 donors. GMT (geometric mean titre) with s.d 544 
presented representative of two independent experiments each with two technical repeats. 545 
Wilcoxon matched-pairs signed rank test, ns not significant. D. ten example neutralisation 546 
curves. Indicated is serum log10 inverse dilution against % neutralisation. Data points 547 
represent means of technical replicates and error bars represent standard deviation. Curves 548 
are representative of two independent experiments. E-G Kinetics of binding to wildtype and 549 
∆H69/V70 NTD of 12 NTD-specific mAbs. E, Biolayer interferometry analysis of binding to 550 
wildtype (WT, black) and WT ∆H69/V70 (red) NTDs by 12 NTD-targeting mAbs. Dotted 551 
lines separate association phase from dissociation phase. Shown is 1 representative 552 
experiment out of 2 independent experiments.  F. Side-by-side comparison of binding to WT 553 
(black) and ∆H69/V70 (red) NTDs by 11 NTD-targeting mAbs. Binding is shown as area 554 
under the curve (AUC). S2L28 mAb is not shown due to too little response measured (< 0.10 555 
nm). G. Binding to NTD of the 11 mAbs shown in B expressed as fold change of AUC of 556 
WT compared to ∆H69/V70. Data are representative of two independent experiments (n=2).  557 
 558 
Figure 3. Spike ∆H69/V70 enhances entry and is accompanied by increased spike S2 559 
incorporation into virions. A. Single round infectivity on different cell targets by spike 560 
∆H69/V70 v WT pseudotyped virus produced in 293T cells. Data are representative of three 561 
independent experiments. Data are shown with mean and st ndard error of mean (SEM) and 562 
the statistics were performed using unpaired Student t t st. B. Infectivity of ∆H69/V70 563 
pseudotyped virus on target HeLa cells transduced with ACE2, expressed as fold change 564 








and of cell lysates of 293T producer cells following transfection with plasmids expressing 566 
lentiviral vectors and SARS-CoV-2 S ∆H69/V70 versus WT (all with D614G), probed with 567 
antibodies for HIV-1 p24 and SARS-Cov-2 S2. D. Quantification of spike:p24 ratio in 568 
supernatants for wild type virus with ∆H69/V70 deletion versus WT alone across multiple 569 
replicate experiments. Mean and SEM are shown; one sample t-test *** p<0.001. E. 570 
Quantification of cleaved S2 spike: full length spike for wild type virus with ∆H69/V70 571 
deletion versus WT alone in virions and cell lysate. Each data point represents a single 572 
experiment. F. Infectivity of ∆H69/V70 pseudotyped virus produced in H1299 lung epith lial 573 
cells on target 293T cells transiently expressing ACE2 and TMPRSS2. G. Western blots of 574 
virions and cell lysates of H1299 lung epithelial producer cells following transfection with 575 
plasmids expressing lentiviral vectors and SARS-CoV-2 S ∆H69/V70 versus WT (all with 576 
D614G). The statistical analysis was performed using u paired Student t test. H. 577 
Quantification of S2:FL ratio in purified virions from H1299 lung epithelial producer cells. 578 
Data from at least two independent experiments are hown (n=2). 579 
 580 
Figure 4. Route of SARS-CoV-2 S mediated virus entry in cell lines is not altered by 581 
∆H69/V70 spike. A. Schematic diagram illustrates spike in producer cells with CMK 582 
targeting and blocking furin cleavage (left panel). In target cells camostat inhibits TMPRSS2 583 
and therefore cell fusion at the plasma membrane, ad E64D blocks cathepsins and targets 584 
the endocytic viral entry (right panel).  B. Western blots show CMK inhibits spike S1/S2 585 
cleavage in the producer cells transfected with S ∆H69/V70 plasmid, and the spikes with 586 
altered S1/S2 cleavage are incorporated onto the virions. Antibodies against HIV-1 p24 and 587 
Spike S2 were used with anti-GAPDH as a loading control. C. The viruses produced from the 588 
transfected 293T cells in the presence of CMK were us d to transduce target cells. The 589 
luciferase reading (RLU) is used as a surrogate for the spike infectivity bearing with various 590 
S2/FL ratios. The data shown are the technical quadruplicates from one experiment and 591 
statical analysis was done using unpaired t test. D. Comparison of infectivity of spike with 592 
polybasic cleavage site deleted (∆PBCS) with and without ∆H69/V70. Impact of ∆H69/V70 593 
is independent of PBCS. E. ∆H69/V70 deletion does not alter the virus entry route. S 594 
pseudotyped lentiviruses bearing either wt S, ∆H69/V70 S or VSV-G was used to transduce 595 
293T-ACE2 or 293T-ACE2/TMPRSS2 cells in the presence of either E64D or camostat at 596 
different drug concentrations. The cells were then arvested after 2 days and assayed for 597 








The data shown are technical duplicates and are repr s ntative of at least two independent 599 
experiments (n=2).  600 
 601 
Figure 5: ∆H69/V70 appears after spike N439K and Y453F and compensates for their 602 
reduced infectivity. A. Maximum likelihood phylogeny of global sequences carrying Spike 603 
mutant A. N439K and B. Y453F. All sequences in the GISAID database containing S:439K 604 
or S: Y453F (18th February 2021) were downloaded, realigned to Wuhan-Hu-1 using 605 
MAFFT and deduplicated. C. Representation of Spike RBM:ACE2 interface (PDB: 6M0J) 606 
with residues N439, Y453 and N501 highlighted as spheres coloured by element. D-F. Spike 607 
mutant ∆H69/V70 compensates for infectivity defect of Spike RBD mutations and is 608 
associated with increased Spike incorporation into viri ns. D. Infectivity of spike (D614G) 609 
∆H69/V70 deletion in absence and presence of Spike RBD mutations. Single round infection 610 
by luciferase expressing lentivirus pseudotyped with SARS-CoV-2 spike protein on target 611 
HeLa cells stably transduced with ACE2. Mean and SEM are shown. E. Representative 612 
western blot of purified virions and cell lysates probed with antibodies against HIV-1 p24, 613 
SARS-CoV-2 spike S2 and GAPDH. F, G. Densitometric quantification of F. spike:P24 and  614 
G. cleaved S2 spike:full length spike ratio for spike (D614G) ∆H69/V70 deletion in absence 615 
and presence of Spike RBD mutations across multiple experiments in pelleted virus. RLU – 616 
relative light units; U – unit of reverse transcriptase activity (RT). Data are representative of 617 
2 independent experiments (n=2). Student t test ***p<0.001 618 
 619 
Figure 6. Spike ∆H69/V70 in B.1.1.7 enhances spike infectivity. A. Surface representation 620 
of spike homotrimer in open conformation with one upright RBD overlaid with ribbon 621 
representation (PDB: 6ZGG, Wrobel et al., 2020), with different monomers shown in black, 622 
pale blue and gold. The deleted residues H69 and V70 and the residues involved in amino 623 
acid substitutions (501, 570, 716, 982 and 1118) and the deletion at position 144 are coloured 624 
red on each monomer and labelled on the monomer with an upright RBD shown in black. 625 
Scissors mark approximate location of an exposed loop (residues 677-688), containing the 626 
furin cleavage site, and including residue 681, which is absent from the structure. 627 
B. A representative infectivity of B.1.1.7 with replacement of H69 and V70 versus B.1.1.7 628 
containing spike ∆H69/V70 and wild type (D614G) spike is shown. Single round infection by 629 
luciferase expressing lentivirus pseudotyped with SAR -CoV-2 Spike protein on HeLa cells 630 
transduced with ACE2. The data represent technical qu druplicates. C. Fold change of 631 








transfected 293T cells, A459-ACE2/TMPRSS2, and H1299 cells. The data shown were from 633 
three independent experiments with each in technical triplicates (one sample t test).   D. A 634 
representative western blot analysis following transfection of 293T cells with spike and 635 
lentiviral plasmids. Virion loading was normalized for input virus using reverse transcriptase 636 
activity. Antibodies against HIV-1 p24 and Spike S2were used with anti-GAPDH as a 637 
loading control. S2 to FL spike was analysed by densitometry and the S2/FL cleavage ratio 638 
was calculated for virions (E) and for cell lysates (F). G. Quantification of spike:p24 ratio for 639 
B.1.1.7 and B.1.1.7 with H69/V70 replacement across three independent experiments (n=3). 640 
** p<0.01, ****p<0.0001. 641 
 642 
Figure 7: ∆H69/V70 significantly accelerates cell-cell fusion activity of B.1.1.7 spike 643 
protein. A. Schematic of cell-cell fusion assay (created with biorender.com). B 644 
Reconstructed images at 6 hours of 293T cells co-transfected with the indicated Spike 645 
mutants and mCherry expressing plasmid mixed with green dye-labelled Vero acceptor cells. 646 
Scale bars represent 100 mm. Green colour identifies th  acceptor cells while red colour 647 
marks donor cells. Merged green-red colours indicate the syncytia. C Quantification of cell-648 
cell fusion kinetics showing percentage of green and red overlap area over time. Mean is 649 
plotted with error bars representing SEM D. Quantification of cell-cell fusion of the indicated 650 
Spike mutants at 6 hours post transfection. Mean is plotted with error bars representing SEM. 651 
E. Representative western blot of cells transfected with the indicated Spike mutants (detected 652 
with anti-S2 antibody). The S2 subunit is indicated with the arrowhead. beta actin is shown as 653 
loading control. Data are representative of at least three independent experiments (n=2). 654 








STAR Methods 663 
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Further information should be directed to and will be fulfilled by the Lead Contact, Ravindra 668 
K. Gupta rkg20@cam.ac.uk. 669 
 670 
Materials Availability 671 
 672 
This study did not generate new unique reagents. 673 
 674 
 675 
Data and Code Availability 676 
 677 
Raw anonymised data are available from the lead conta t without restriction. 678 
 679 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 680 
The study was primarily a laboratory based study using pseudotyped virus (PV) with 681 
mutations generates by site directed mutagenesis. We tested infectivity in cell lines with a 682 
range of drug inhibitors and monoclonal antibodies. Sensitivity to antibodies in serum was 683 
tested using convalescent sera from recovered individuals collected as part of the Cambridge 684 
NIHR Bioresource. We also performed phylogenetic analyses of data available publicly in 685 
GISAID. 686 
 687 
Ethical approval 688 
Ethical approval for use of serum samples. Controls with COVID-19 were enrolled to the 689 
NIHR BioResource Centre Cambridge under ethics review board (17/EE/0025). 690 
 691 
METHOD DETAILS 692 
 693 
Phylogenetic Analysis 694 
All available full-genome SARS-CoV-2 sequences were downloaded from the GISAID 695 
database (http://gisaid.org/)(Shu and McCauley, 2017) on 16th February 2021. Low-quality 696 
sequences (>5% N regions) were removed, leaving a dat set of 491,395 sequences with a 697 
length of >29,000bp. Sequences were deduplicated and then filtered to find the mutations of 698 
interest. All sequences were realigned to the SARS-CoV 2 reference strain MN908947.3, 699 
using MAFFT v7.475 with automatic strategy selection and the --keeplength --addfragments 700 
options (Katoh and Standley, 2013). Major SARS-CoV-2 clade memberships were assigned 701 








v2.4.2(Rambaut et al., 2020) (github.com/cov-lineages/pangolin) and a local instance of the 703 
PangoLEARN model, dated 18th April 21:49 (https://github.com/cov-704 
lineages/pangoLEARN).  705 
  706 
Maximum likelihood phylogenetic trees were produced using the above curated dataset using 707 
IQ-TREE v2.1.2 (Minh et al., 2020). Evolutionary model selection for trees were inferred 708 
using ModelFinder (Kalyaanamoorthy et al., 2017) and trees were estimated using the 709 
GTR+F+I model with 1000 ultrafast bootstrap replicates (Minh et al., 2013). All trees were 710 
visualised with Figtree v.1.4.4 (http://tree.bio.ed.ac.uk/software/figtree/) and ggtree v2.2.4 711 
rooted on the SARS-CoV-2 reference sequence and nodes arranged in descending order. 712 
Nodes with bootstraps values of <50 were collapsed using an in-house script. 713 
 714 
To reconstruct a phylogeny for the 69/70 spike region of the 20 Sarbecoviruses examined in 715 
Figure 5, Rdp5(Martin et al., 2015) was used on the codon spike alignment to determine the 716 
region between amino acids 1 and 256 as putatively non-recombinant. A tree was 717 
reconstructed using the nucleotide alignment of this region under a GTR+Γ substitution 718 
model with RAxML-NG(Kozlov et al., 2019). Node support was calculated with 1000 719 
bootstraps. Alignment visualisation was done using BioEdit(Hall et al., 2011).  720 
 721 
Structural modelling 722 
The structure of the post-deletion NTD (residues 14-306) was modelled using I-723 
TASSER(Roy et al., 2010), a method involving detection of templates from the protein data 724 
bank, fragment structure assembly using replica-exchange Monte Carlo simulation and 725 
atomic-level refinement of structure using a fragment-guided molecular dynamics simulation. 726 
The structural model generated was aligned with the spike structure possessing the pre-727 
deletion conformation of the 69-77 loop (PDB 7C2L(Chi et al., 2020)) using PyMOL 728 
(Schrödinger). Figures prepared with PyMOL using PDBs 7C2L, 6M0J (Lan et al., 2020), 729 
6ZGE28 and 6ZGG (Wrobel et al., 2020). 730 
 731 
RNA secondary structure modelling. 732 
2990 nucleotides centred around the spike protein amino acids 69-70 from SARS-CoV2 733 
sequence from an individual12 were aligned in CLUSATL-Omega (nucleotides 20277-23265 734 
of the Wuhan isolate MN908947.3) and a consensus structure was generated using 735 










HEK 293T CRL-3216, Vero CCL-81 were purchased from ATCC and maintained in 739 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal calf serum 740 
(FCS), 100 U/ml penicillin, and 100mg/ml streptomycin. All cells are regularly tested and are 741 
mycoplasma free. H1299 cells were a kind gift from Sam Cook. Calu-3 cells were a kind gift 742 
from Paul Lehner, A549 A2T2(Rihn et al., 2021) cells were a kind gift from Massimo 743 
Palmerini. 744 
 745 
Pseudotype virus preparation 746 
Plasmids encoding the spike protein of SARS-CoV-2 D614 with a C terminal 19 amino acid 747 
deletion with D614G, were used as a template to produce variants lacking amino acids at 748 
position H69 and V70, as well as mutations N439K and Y453F. Mutations were introduced 749 
using Quickchange Lightning Site-Directed Mutagenesis kit (Agilent) following the 750 
manufacturer’s instructions. B.1.1.7 S expressing plasmid preparation was described 751 
previously, but in brief was generated by step wise mutagenesis. Viral vectors were prepared 752 
by transfection of 293T cells by using Fugene HD transfection reagent (Promega). 293T cells 753 
were transfected with a mixture of 11ul of Fugene HD, 1µg of pCDNA∆19 spike-HA, 1ug of 754 
p8.91 HIV-1 gag-pol expression vector and 1.5µg of pCSFLW (expressing the firefly 755 
luciferase reporter gene with the HIV-1 packaging signal). Viral supernatant was collected at 756 
48 and 72h after transfection, filtered through 0.45um filter and stored at -80˚C as previously 757 
described. Infectivity was measured by luciferase detection in target 293T cells transfected 758 
with TMPRSS2 and ACE2. 759 
 760 
SARS-CoV-2 D614 (Wuhan) and RaTG13 mutant plasmids and infectivity  761 
Plasmids encoding the full-length spike protein of SARS-CoV-2 D614 (Wuhan) and 762 
RaTG13, in frame with a C – terminal Flag tag(Conceicao et al., 2020), were used as a 763 
template to produce variants lacking amino acids at position H69 and V70. The deletion was 764 
introduced using Quickchange Lightning Site-Directed Mutagenesis kit (Agilent) following 765 
the manufacturer’s instructions. Viruses were purified by ultracentrifugation; 25mL of crude 766 
preparation being purified on a 20% sucrose cushion at 2300rpm for 2 hrs at 4˚C. After 767 
centrifugation, the supernatant was discarded and the viral pellet resuspended in 600 µL 768 
DMEM (10% FBS) and stored at -80˚C. Infectivity was examined in HEK293 cells 769 








pseudotyped virus preparation by PERT assay. Western blots were performed on purified 771 
virus with anti-HIV1 p24, 1:1,000 (Abcam) or anti-FLAG, 1:2,000 (Sigma) antibodies used 772 
following SDS-PAGE and transfer.  773 
 774 
Standardisation of virus input by SYBR Green-based product-enhanced PCR assay (SG-775 
PERT) 776 
The reverse transcriptase activity of virus preparations was determined by qPCR using a 777 
SYBR Green-based product-enhanced PCR assay (SG-PERT) as previously 778 
described(Vermeire et al., 2012). Briefly, 10-fold dilutions of virus supernatant were lysed in 779 
a 1:1 ratio in a 2x lysis solution (made up of 40% glycerol v/v 0.25% Trition X-100 v/v 780 
100mM KCl, RNase inhibitor 0.8 U/ml, TrisHCL 100mM, buffered to pH7.4) for 10 minutes 781 
at room temperature. 782 
 783 
12µl of each sample lysate was added to thirteen 13µl of a SYBR Green master mix 784 
(containing 0.5µM of MS2-RNA Fwd and Rev primers, 3.5pmol/ml of MS2-RNA, and 785 
0.125U/µl of Ribolock RNAse inhibitor and cycled in a QuantStudio. Relative amounts of 786 
reverse transcriptase activity were determined as the rate of transcription of bacteriophage 787 
MS2 RNA, with absolute RT activity calculated by comparing the relative amounts of RT to 788 
an RT standard of known activity. 789 
 790 
Generation of Coronavirus-like particles and western blotting  791 
Plasmids encoding codon-optimised (M)embrane, (E)nvelope and (N)ucleocapsid proteins of 792 
SARS-CoV-2 were a kind gift from Nevan Krogan (M, pLVX-EF1alpha-SARS-CoV-2-M-793 
2xStrep-IRES-Puro, Addgene #141386; E, pLVX-EF1alph-SARS-CoV-2-E-2xStrep-IRES-794 
Puro, Addgene #141385; N, pLVX-EF1alpha-SARS-CoV-2-N xStrep-IRES-Puro, Addgene  795 
#141391) (Gordon et al., 2020). For expression in 293T cells, M, E and N were each 796 
subcloned into a modified pmaxGFP (Lonza) vector as M/E/N-IRES-GFP. Plasmids 797 
encoding the (S)pike protein of SARS-CoV-2 with a C-terminal 19 amino acid deletion 798 
plus/minus the ∆H69/V70 deletion are described above (pseudotype virus preparation).  799 
Coronavirus-like particles were prepared essentially s previously described (Swann et al., 800 
2020; Yurkovetskiy et al., 2020). In brief, 4e6 293T cells in 10 cm dishes were transfected 801 
using TransIT-LT1 (Mirus) with a total of 4 µg DNA comprising 1 µg each of plasmids 802 








Supernatants containing coronavirus-like particles w re harvested after 2 d, spun for 10 min 804 
at 2,000g, then passed through a 0.45 µm filter. Fo each condition, 9 ml supernatant was 805 
layered on a 2 ml cushion of 20% sucrose in PBS and spun for 2 h at 100,000g in a Type 70 806 
Ti Beckman Coulter Ultracentrifuge Rotor. The pellet was washed once with PBS, then 807 
resuspended in 100 µl 2% SDS in PBS. After aspiration of supernatant, cells were washed 808 
twice in PBS, then lysed in 800 µl of 2% SDS in TBS with 500 units of Benzonase (Sigma-809 
Aldrich). Lysates were incubated for 30 m at room temperature, then spun for 10 min at 810 
13,000g. 811 
Resuspended pellets containing concentrated coronavi us-like particles were heated in 812 
Laemmli buffer with DTT at 95 °C for 5 min. For each ondition, 30 µl was loaded on a 4-813 
20% Mini-PROTEAN TGX Precast Protein Gel (Bio-Rad). Cell lysates were quantified 814 
using the Pierce BCA Protein Assay Kit (Thermo Scientific), then heated in Laemmli buffer 815 
with DTT at 95 °C for 5 min. For each condition, 20µg protein was loaded on an identical 816 
gel. Proteins were transferred to 45 nm PDVF membranes and blocked with 5% milk in PBS-817 
Tween 0.2%. The following antibodies were used for immunoblotting: anti-S (Invitrogen, 818 
PA1-41165); anti-N (Novus Biologicals, NB100-56683) and anti-β-actin (Sigma, A5316).  819 
 820 
Spike cleavage inhibition experiments 821 
CMK furin inhibitor experiments: 293T cells were transfected with plasmids expressing 822 
Gag/pol, luciferase and spike.  Furin inhibitor CMK (Calbiochem) was added at either 5 M or 823 
25 uM concentration three hours post transfection. The supernatants and cell lysates were 824 
collected after 48 hours for infectivity measurement o  target cells or for western blotting. 825 
 826 
E64D and Camostat experiments: ACE2 or ACE2 and TMPRSS2 transfected 293T cells 827 
were either E64D (Tocris) or camostat (Sigma-Aldrich) treated for 3 hours at each drug 828 
concentration before the addition of a comparable amount of input viruses pseudotyped with 829 
WT, 6970 deletion or VSV-G (approx. 1 million RLU). The cells were then left for 48 hours 830 
before addition of substrate for luciferase (Promega) and read on a Glomax plate reader 831 
(Promega). The RLU was normalised against the no-drug control which was set as 100%. 832 
 833 
Cell-cell fusion assay  834 
Cell fusion assay was carried out as previously described(Papa et al., 2021). Briefly, Vero 835 
cells and 293T cells were seeded at 80% confluency in a 24 multiwell plate. 293T cells were 836 








using Fugene 6 and following the manufacturer’s instructions (Promega). Vero cells were 838 
treated with CellTracker™ Green CMFDA (5-chloromethylfluorescein diacetate) (Thermo 839 
Scientific) for 20 minutes. 293T cells were then detached 5 hours post transfection, mixed 840 
together with the green-labelled Vero cells, and plated in a 12 multiwell plate. Cell-cell 841 
fusion was measured using an Incucyte and determined as the proportion of merged area to 842 
green area over time. Data were then analysed using Incucyte software analysis. Data were 843 
normalised to cells transfected only with mCherry potein and mixed with green labelled 844 
Vero cells. Graphs were generated using Prism 8 software. 845 
 846 
Western blotting 847 
Cells were lysed and supernatants collected 18 hours post transfection. Purified virions were 848 
prepared by harvesting supernatants and passing throug  a 0.45 µm filter. Clarified 849 
supernatants were then loaded onto a thin layer of 8.4% optiprep density gradient medium 850 
(Sigma-Aldrich) and placed in a TLA55 rotor (Beckman Coulter) for ultracentrifugation for 2 851 
hours at 20,000 rpm. The pellet was then resuspended for western blotting. Cells were lysed 852 
with cell lysis buffer (Cell signalling) or were treated with Benzonase Nuclease (70664 853 
Millipore) and boiled for 5 min. Samples were then run on 4%–12% Bis Tris gels and 854 
transferred onto nitrocellulose or PVDF membranes using an iBlot or semidry (Life 855 
Technologies and Biorad, respectively). 856 
 857 
Membranes were blocked for 1 hour in 5% non-fat milk in PBS + 0.1% Tween-20 (PBST) at 858 
room temperature with agitation, incubated in primay ntibody (anti-SARS-CoV-2 Spike, 859 
Invitrogen, PA1-41165), anti-GAPDH (proteintech) or anti-p24 (NIBSC)) diluted in 5% non-860 
fat milk in PBST for 2 hours at 4°C with agitation, washed four times in PBST for 5 minutes 861 
at room temperature with agitation and incubated in secondary antibody (anti-rabbit or anti-862 
mouse HRP conjugate), anti-bactin HRP (sc-47778) diluted in 5% non-fat milk in PBST for 1 863 
hour with agitation at room temperature. Membranes w re washed four times in PBST for 5 864 
minutes at room temperature and imaged directly using a ChemiDoc MP imaging system 865 
(Bio-Rad).  866 
 867 
Serum pseudotype neutralisation assay 868 
Spike pseudotype assays have been shown to have similar characteristics as neutralisation 869 
testing using fully infectious wild type SARS-CoV-2(Schmidt et al., 2020).Virus 870 








TMPRSS2 using SARS-CoV-2 spike pseudotyped virus expressing luciferase(Mlcochova et 872 
al., 2020a). Pseudotyped virus was incubated with serial dilution of heat inactivated human 873 
serum samples or convalescent plasma in duplicate for 1h at 37˚C. Virus and cell only 874 
controls were also included. Then, freshly trypsinized 293T ACE2/TMPRSS2 expressing 875 
cells were added to each well. Following 48h incubation in a 5% CO2 environment at 37°C, 876 
the luminescence was measured using Steady-Glo Luciferase assay system (Promega).  877 
 878 
Monoclonal antibody neutralisation of B.1.1.7 or B.1.1.7 H69/V70 pseudotyped viruses 879 
Preparation of B.1.1.7 or B.1.1.7 H69/V70 SARS-CoV-2 S glycoprotein-encoding-plasmid 880 
used to produce SARS-CoV-2-MLV based on overlap extension PCR. Briefly, a modification 881 
of the overlap extension PCR protocol(Forloni et al., 2018) was used to introduce the 9 or 882 
7 mutations of the B.1.1.7 and B.1.1.7 H69/V70 lineag s, respectively. In a first step, 9 DNA 883 
fragments with overlap sequences were amplified by PCR from a plasmid (phCMV1, 884 
Genlantis) encoding the full-length SARS-CoV-2 S gene (BetaCoV/Wuhan-Hu-1/2019, 885 
accession number mn908947). The mutations (del-69/70, del-144, N501Y, A570D, D614G, 886 
P681H, S982A, T716I and D1118H or K417N, E484K and N501Y) were introduced by 887 
amplification with primers with similar Tm. Deletion of the C-terminal 21 amino acids was 888 
introduced to increase surface expression of the recombinant S(Case et al., 2020). Next, 3 889 
contiguous overlapping fragments were fused by a first overlap PCR (step 2) using the 890 
utmost external primers of each set, resulting in 3 larger fragments with overlapping 891 
sequences. A final overlap PCR (step 3) was performed on the 3 large fragments using the 892 
utmost external primers to amplify the full-length S gene and the flanking sequences 893 
including the restriction sites KpnI and NotI. This fragment was digested and cloned into the 894 
expression plasmid phCMV1. For all PCR reactions the Q5 Hot Start High fidelity DNA 895 
polymerase was used (New England Biolabs Inc.), according to the manufacturer’s 896 
instructions and adapting the elongation time to the size of the amplicon. After each PCR step 897 
the amplified regions were separated on agarose gel and purified using Illustra GFX™ PCR 898 
DNA and Gel Band Purification Kit (Merck KGaA). 899 
 900 
Ab discovery and recombinant expression 901 
Human mAbs were isolated from plasma cells or memory B cells of SARS-CoV or SARS-902 
CoV-2 immune donors, as previously reported. Recombinant antibodies were expressed in 903 








Transfected cells were supplemented 1 day after transfection with ExpiCHO Feed and 905 
ExpiFectamine CHO Enhancer. Cell culture supernatant was collected eight days after 906 
transfection and filtered through a 0.2 µm filter. Recombinant antibodies were affinity 907 
purified on an ÄKTA xpress FPLC device using 5 mL HiTrap™ MabSelect™ PrismA 908 
columns followed by buffer exchange to Histidine buffer (20 mM Histidine, 8% sucrose, pH 909 
6) using HiPrep 26/10 desalting columns.   910 
 911 
Pseudovirus neutralization assay for testing NTD monoclonal antibodies 912 
MLV-based SARS-CoV-2 S-glycoprotein-pseudotyped viruses were prepared as previously 913 
described (Pinto et al., 2020). HEK293T/17cells were cotransfected with a WT, B.1.1.7 or 914 
B.1.1.7 H69/V70 SARS-CoV-2 spike glycoprotein-encoding-plasmid, an MLV Gag-Pol 915 
packaging construct and the MLV transfer vector encoding a luciferase reporter using X-916 
tremeGENE HP transfection reagent (Roche) according to the manufacturer’s instructions. 917 
Cells were cultured for 72 h at 37°C with 5% CO2 before harvesting the supernatant. VeroE6 918 
stably expressing human TMPRSS2 were cultured in Dulbecco’s Modified Eagle’s Medium 919 
(DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin–streptomycin (100 I.U. 920 
penicillin/mL, 100 µg/mL), 8 µg/mL puromycin and plated into 96-well plates for 16–24 h. 921 
Pseudovirus with serial dilution of mAbs was incubated for 1 h at 37°C and then added to the 922 
wells after washing 2 times with DMEM. After 2–3 h DMEM containing 20% FBS and 2% 923 
penicillin–streptomycin was added to the cells. Following 48-72 h of infection, Bio-Glo 924 
(Promega) was added to the cells and incubated in the dark for 15 min before reading 925 
luminescence with Synergy H1 microplate reader (BioTek). Measurements were done in 926 
duplicate and relative luciferase units were converted to percent neutralization and plotted 927 
with a non-linear regression model to determine IC50 values using GraphPad PRISM 928 
software (version 9.0.0). 929 
 930 
QUANTIFICATION AND STATISTICAL ANALYSIS 931 
 932 
Infectivity assays, drug inhibitor assays 933 
Measurements were done in duplicate and relative luciferase units measured with a Glomax 934 
luminometer. Data were analysed using GraphPad PRISM software (version 9.0.0). 935 
Statistical tests are described in the figure legends along n, mean and standard 936 









Neutralisation assays 939 
Measurements were done in duplicate and relative luciferase units were converted to percent 940 
neutralization against no-drug control which was set a  100%. Data were plotted with a non-941 
linear regression model to determine IC50 values using GraphPad PRISM software (version 942 
9.0.0). The 50% inhibitory dilution (EC50) was defined as the serum dilution at which the 943 
relative light units (RLUs) were reduced by 50% compared with the virus control wells (virus 944 
+ cells) after subtraction of the background RLUs in the control groups with cells only. The 945 
EC50 values were calculated with non-linear regression, log (inhibitor) versus normalized 946 
response using GraphPad Prism 8 (GraphPad Software, Inc., San Diego, CA, USA). The 947 
neutralisation assay was positive if the serum achieved at least 50% inhibition at 1 in 3 948 
dilution of the SARS-CoV-2 spike protein pseudotyped virus in the neutralisation assay. The 949 
neutralisation result was negative if it failed to achieve 50% inhibition at 1 in 3 dilution. 950 
Statistical tests are described in the figure legends along with the value of n, mean and 951 




Key Resources Table 956 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Anti-HIV p24 Abcam Cat#Ab9071 
Anti-FLAG Sigma Aldrich Cat#F7425 
Anti-SARS-CoV-2 spike Novusbio Cat#NB100-56578 
RNA (MS2) Roche Cat#10165948001 
HIV RT Milipore Cat#382129 
Anti-rabbit HRP conjugate Cell Signaling Cat#7074 
Bacterial and virus strains  
XL1-blue cells Agilent Cat#200249 
Biological samples   
Chemicals, peptides, and recombinant proteins 
TransIT-X2 Mirus Cat#MIR 6000 
Polyethylenimine (PEI) Sigma Aldrich Cat#408727 
Critical commercial assays 
Bright-Glo Promega Cat#E2650 
QuikChange Lightning Agilent Cat#210518 
Luna Universal qPCR Master Mix New England Biolabs Cat#M3003L 
Deposited data 
Experimental models: Cell lines 
HEK 293T ATCC Cat#CRL-3216 









MS2 FP: 5’-TCCTGCTCAACTTCCTGTCGAG-3’ This paper N/A 
MS2 RP: 5′-CACAGGTCAAACCTCCTAGGAATG-3′ This paper N/A 
Spike_∆69/70 FP1: 5’- 
GGTTCCACGCCATCAGCGGCACAAACGG-3’ 
This paper N/A 
Spike_∆69/70 FP2: 5’- 
GCGCTAATTTAAGCTTGCCACCATGTTCGTG -3’ 
This paper N/A 
Spike_∆69/70 RP1: 5’- 
CCGTTTGTGCCGCTGATGGCGTGGAACC -3’ 
This paper N/A 
Spike_∆69/70 RP2: 5’- 
TAATGGGTCCCTCACGGCGTCGGTTG -3’ 




This paper N/A 
Spike_furin_KO_FP2: 5’- 
GGCCCGCCGAGGGGAGTTTGTCTGGGTCTG-3’ 




This paper N/A 
Spike_furin_KO_RP2: 5’-CGGGCCCTCTAGACTCGAGC 
GCCTACTTATCATCATCATCCTTATAGTCAGTGTAGTGC-3’ 
This paper N/A 
Recombinant DNA 
Plasmid: SARS-CoV-2 spike D614-FLAG Biobasic N/A 
Plasmid: RaTG13 spike-FLAG Biobasic N/A 
Plasmid: human ACE2 receptor Biobasic N/A 
Plasmid: TMPRSS2 Biobasic N/A 
Plasmid: p8.91 This paper N/A 
Plasmid: CSFLW This paper N/A 
Plasmid: pcDNA3.1 Thermo Scientific, 
Invitrogen 
Cat#V66020 
Software and algorithms 
Pangolin v2.4.2 (Rambaut et al., 2020) https://github.com/co
v-lineages/pangolin 
IQTREE2 v2.1.2 (Minh et al., 2020) http://www.iqtree.org
/ 
ModelFinder  (Kalyaanamoorthy et 
al., 2017) 
NA 
Figtree v1.4.4 (Rambaut, 2012) http://tree.bio.ed.ac.
uk/software/figtree/ 
RDP5 (Martin et al., 2020) http://web.cbio.uct.a
c.za/~darren/rdp.htm
l 
RAXML-NG v1.02 (Kozlov et al., 2019) https://github.com/a
mkozlov/raxml-ng 
BioEdit v7.2 (Bhullar et al., 2012) NA 




I-TASSER (Roy et al., 2010)  
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• Spike H69/V70 does not confer escape from antibodies 
• Spike H69/V70 increases cleaved S2 and spike infectivity  
• B.1.1.7 requires H69/V70 for efficient cleaved spike incorporation and infectivity 
• B.1.1.7 spike requires H69/V70 for rapid syncytia formation  
 
ETOC blurb 
Meng et al. report that the SARS-CoV-2 spike H69/V70 deletion has arisen multiple times. 
The deletion increases entry efficiency, is associated with increased cleaved spike in virions 
and can compensate for loss of infectivity. The B.1.1.7 spike requires the H69/V70 deletion 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4. Route of SARS-CoV-2 S mediated virus entry in cell lines is not altered by ΔH69/V70 spike. A. Schematic diagram 
illustrates spike in producer cells with CMK targeting and blocking furin cleavage (left panel). In target cells camostat inhibits 
TMPRSS2 and therefore cell fusion at the plasma membrane, and E64D blocks cathepsins and targets the endocytic viral 
entry (right panel).  B. Western blots show CMK inhibits spike S1/S2 cleavage in the producer cells transfected with S 
ΔH69/V70 plasmid, and the spikes with altered S1/S2 cleavage are incorporated onto the virions. Antibodies against HIV-1 
p24 and Spike S2 were used with anti-GAPDH as a loading control. C. The viruses produced from the transfected 293T cells 
in the presence of CMK were used to transduce target cells. The luciferase reading (RLU) is used as a surrogate for the spike
infectivity bearing with various S2/FL ratios. The data shown are the technical quadruplicates from one experiment and 
statical analysis was done using unpaired t test. D. Comparison of infectivity of spike with polybasic cleavage site deleted 
(ΔPBCS) with and without ΔH69/V70, indicating the impact of ΔH69/V70 is independent of PBCS. E. ΔH69/V70 deletion does 
not alter the virus entry route. S pseudotyped lentiviruses bearing either wt S, ΔH69/V70 S or VSV-G was used to transduce 
293T-ACE2 or 293T-ACE2/TMPRSS2 cells in the presence of either E64D or camostat at different drug concentrations. The 
cells were then harvested after 2 days and assayed for luciferase expression, which was then normalised against the non-
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Supplementary Figure 1: Infectivity and cleavage of spike 𝚫H69/V70 in a background of D614 (Wuhan) in 
pseudotyped lentivirus. Sucrose purified pseudotypes, as indicated, were used to infect human ACE2 expressing 
HEK293 cells, with luciferase readings read at 72 hours post infection. Experiments were performed in biological 
quadruplicate with the mean and standard deviation plotted. Results are representative of experiments performed 
two times. Statistical significance was assessed using an unpaired t-test (ns; non-significant, ***; <0.005). Western 
blot of purified pseudotype virus. Spike and HIV pseudotype abundances were assessed using Flag and p24 
antibodies, respectively. Relative spike expression was calculated by densitometry using Image J. Briefly, inverted 
pixel intensities for spike and p24 bands were first normalised to a background region of the gel. Spike protein 
intensities were then normalised to p24 intensity before mutant protein expression was calculated as a factor of 
wild-type protein.  NE: no envelope/spike. C, D. Cleavage of spike 𝚫H69/V70 versus WT (D614G background) 
in coronavirus like particles. C. Generation of coronavirus-like particles. Supernatants containing coronavirus-
like particles were concentrated by ultracentrifugation, then analysed by immunoblot in parallel with lysates from 
producer cells D. Immunoblots of cell lysates and coronavirus-like particles from (A). 293T cells were transfected 
with plasmids encoding the indicated SARS-CoV-2 proteins (S, spike, WT or ∆H69/V70; M, membrane; E, 
envelope; N, nucleocapsid). Cells transfected with WT or ∆H69/V70 S alone (no M, E or N) were included as 
controls. Arrow heads indicate cleaved S in coronavirus-like particles. Representative data are shown from three 
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Supplementary Figure 2: Maximum likelihood phylogeny of UK viruses bearing 𝚫69/70 and N501Y mutations.
Two distinct lineages of the 𝚫H69/V70 were observed to expand in the UK, separately from the 501Y lineage. Prior to
expansion of the B.1.1.7 lineage, clusters of infections bearing either N501Y or 𝚫H69/V70 were observed. Alongside
expansion of the B.1.1.7 lineage, is a population in Wales that carries 501Y, but no 𝚫H69/V70. An intermediary was
detected alongside the B.1.1.7 lineage (indicated on phylogeny) which had only a subset of the mutations that make up













Supplementary Figure 3: Neutralisation and binding by a panel of NTD-specific mAbs against WT, B.1.1.7 
and B.1.1.7 H69/V70 mutant SARS-CoV-2 viruses. A. Neutralisation of WT (black), B.1.1.7 (blue) and B.1.1.7 
H69/V70 replacement mutant (red) pseudotyped SARS-CoV-2-MLVs by 6 selected mAbs from one experiment. 
B. Neutralisation of WT, B.1.1.7 and B.1.1.7 H69/V70 SARS-CoV-2-MLVs by 13 mAbs targeting NTD. Shown 
are the mean IC50 values (ng/ml) from one experiment. The higher the IC50 the less sensitive the virus to 
antibodies. C. Neutralisation shown as mean IC50 values (upper panel) and mean fold change of B.1.1.7 (blue) or 
B.1.1.7 H69/V70 (red) relative to WT (lower panel) of the 13 NTD mAbs tested. Lower panel shows IC50 values 








Supplementary Figure 4. Comparison of the H69/V70 deletion site to other Sarbecoviruses. A. phylogeny for the
Spike peptide region 1-256 B. protein sequences from 20 Sarbecoviruses, including SARS-CoV-2 (Wuhan-Hu-1) and
SARS-CoV (HSZ-Cc), with distinct genotypes at the Spike region around amino acid positions 69 and 70 (highlighted
in yellow box). The 69/70 HL insertion in the P2V sequence from the Guangxi pangolin virus cluster and the HV
convergent insertion in the RShSTT182/200 bat virus sequences are highlighted. C. The nucleotide alignment between
SARS-CoV-2 Wuhan-Hu-1, B.1.1.7, the bat sarbecovirus RaTG13 RShSTT182/200 and the Guangxi pangolin viruses
shows the difference between the out-of-frame deletion observed in the former and the in-frame deletion in the latter.
D. Single round infection by luciferase expressing lentivirus pseudotyped with RaTG13 Spike protein on 293T cells
transduced with ACE2. Experiments were performed in biological quadruplicate with the mean and standard deviation
plotted. Results are representative of experiments performed two times. Statistical significance was assessed using an
unpaired t-test (ns; non-significant, ***; <0.005). E. Representative western blot of supernatant from virus producer
cells. Spike and HIV pseudotype abundances were assessed using Flag and p24 antibodies, respectively. Relative
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Supplementary Figure 5: The positions of common deletion mutations on the RNA structure of the Spike Δ69-70 region 
of the gRNA. The optimal secondary structure was generated from a consensus alignment of human SARS-CoV2 RNAs using 
RNAalifold. Figure shows nucleotides 20277-23265. Base-pair probability, representative of the breadth of the structural 
ensemble that could be adopted by the RNA, is shown in colour according to the key. Relates to Figure 7.
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